BR0316307A - Compostos, processo de preparação dos mesmos, composição farmacêutica e utilização dos compostos - Google Patents

Compostos, processo de preparação dos mesmos, composição farmacêutica e utilização dos compostos

Info

Publication number
BR0316307A
BR0316307A BR0316307-5A BR0316307A BR0316307A BR 0316307 A BR0316307 A BR 0316307A BR 0316307 A BR0316307 A BR 0316307A BR 0316307 A BR0316307 A BR 0316307A
Authority
BR
Brazil
Prior art keywords
compounds
preparation process
pharmaceutical composition
medicaments
formula
Prior art date
Application number
BR0316307-5A
Other languages
English (en)
Inventor
Jean-Marie Ruxer
Jean-Michel Lefrancois
Bertrand Hackmann
Original Assignee
Proskelia Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proskelia Sas filed Critical Proskelia Sas
Publication of BR0316307A publication Critical patent/BR0316307A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTOS, PROCESSO DE PREPARAçãO DOS MESMOS, COMPOSIçãO FARMACêUTICA E UTILIZAçãO DOS COMPOSTOS". A invenção tem por objeto os compostos de fórmula (I), em que R~ 1~, R~ 2~, R~ 3~, R~ 4~ e G tem os significados indicados na descrição, seu processo de preparação, sua aplicação a título de medicamentos tendo uma atividade antagonista do receptor da vitronectina e as composições farmacêuticas contendo os mesmos.
BR0316307-5A 2002-11-19 2003-11-12 Compostos, processo de preparação dos mesmos, composição farmacêutica e utilização dos compostos BR0316307A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
PCT/FR2003/003349 WO2004048375A1 (fr) 2002-11-19 2003-11-12 Nouveaux derives antagonistes du recepteur de la vitronectine leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
BR0316307A true BR0316307A (pt) 2005-09-27

Family

ID=32187700

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316307-5A BR0316307A (pt) 2002-11-19 2003-11-12 Compostos, processo de preparação dos mesmos, composição farmacêutica e utilização dos compostos

Country Status (28)

Country Link
US (2) US7582640B2 (pt)
EP (2) EP2070914B1 (pt)
JP (1) JP4567459B2 (pt)
KR (1) KR101140752B1 (pt)
CN (2) CN101928287A (pt)
AR (2) AR042068A1 (pt)
AT (2) ATE518842T1 (pt)
AU (2) AU2003299330B2 (pt)
BR (1) BR0316307A (pt)
CA (1) CA2506310C (pt)
CO (1) CO5700761A2 (pt)
CY (1) CY1112218T1 (pt)
DE (1) DE60327712D1 (pt)
DK (2) DK2070914T3 (pt)
ES (2) ES2325616T3 (pt)
FR (1) FR2847254B1 (pt)
HK (2) HK1076277A1 (pt)
IL (2) IL168136A (pt)
MA (1) MA27492A1 (pt)
MX (1) MXPA05005340A (pt)
NO (1) NO20052491L (pt)
PL (1) PL376866A1 (pt)
PT (2) PT1565467E (pt)
RU (1) RU2412185C2 (pt)
SI (2) SI2070914T1 (pt)
TW (1) TW200412969A (pt)
WO (1) WO2004048375A1 (pt)
ZA (1) ZA200502850B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
EP3837257A1 (en) 2018-08-17 2021-06-23 Oxurion NV Integrin antagonists
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
EP4171212A1 (en) 2020-06-29 2023-05-03 Ickovic & Bliss, Inc. Systems, methods, and program products for digital pet identification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
CA2144762A1 (en) 1992-10-14 1994-04-28 George D. Hartman Fibrinogen receptor antagonists
EP0673247A4 (en) 1992-12-01 1996-05-01 Merck & Co Inc FIBRINOGEN RECEPTOR ANTAGONISTS.
WO1995032710A1 (en) 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
JPH10504808A (ja) 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
KR20000022190A (ko) 1996-06-28 2000-04-25 플레믹 크리스티안 인테그린 저해제로서의 페닐알라닌 유도체
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
CN1177832C (zh) 1998-01-23 2004-12-01 艾文蒂斯药品德国股份有限公司 作为骨重吸收抑制剂和作为细胞粘附抑制剂的新的磺酰胺衍生物
JP2003504301A (ja) * 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
KR20010086355A (ko) * 1998-08-07 2001-09-10 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 비트로넥틴 수용체 길항제
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
CN1197645C (zh) * 1999-10-05 2005-04-20 德比尔斯工业钻石股份有限公司 金刚石晶簇的生长
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
ZA200502850B (en) 2005-10-25
DK2070914T3 (da) 2011-11-21
CN101928287A (zh) 2010-12-29
CN1738817A (zh) 2006-02-22
CA2506310C (fr) 2014-04-08
CN1738817B (zh) 2011-12-21
MXPA05005340A (es) 2005-11-17
IL205693A (en) 2011-06-30
ES2325616T3 (es) 2009-09-10
JP4567459B2 (ja) 2010-10-20
PT2070914E (pt) 2011-10-12
NO20052491D0 (no) 2005-05-23
US20090149476A1 (en) 2009-06-11
US20060052398A1 (en) 2006-03-09
RU2005119163A (ru) 2006-02-27
FR2847254B1 (fr) 2005-01-28
US7582640B2 (en) 2009-09-01
FR2847254A1 (fr) 2004-05-21
IL168136A (en) 2012-06-28
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
ES2369561T3 (es) 2011-12-01
HK1129372A1 (en) 2009-11-27
WO2004048375A1 (fr) 2004-06-10
DK1565467T3 (da) 2009-09-14
EP2070914A1 (fr) 2009-06-17
AU2009212779B2 (en) 2011-09-01
EP1565467B1 (fr) 2009-05-20
HK1076277A1 (en) 2006-01-13
AR077476A2 (es) 2011-08-31
TW200412969A (en) 2004-08-01
NO20052491L (no) 2005-05-23
KR101140752B1 (ko) 2012-05-03
AU2009212779A1 (en) 2009-09-17
ATE518842T1 (de) 2011-08-15
PT1565467E (pt) 2009-07-15
EP2070914B1 (fr) 2011-08-03
AU2003299330A1 (en) 2004-06-18
AR042068A1 (es) 2005-06-08
CA2506310A1 (fr) 2004-06-10
CY1112218T1 (el) 2015-12-09
AU2003299330B2 (en) 2009-09-17
SI1565467T1 (sl) 2009-10-31
RU2412185C2 (ru) 2011-02-20
CO5700761A2 (es) 2006-11-30
ATE431825T1 (de) 2009-06-15
DE60327712D1 (de) 2009-07-02
EP1565467A1 (fr) 2005-08-24
JP2006508999A (ja) 2006-03-16
SI2070914T1 (sl) 2012-02-29
PL376866A1 (pl) 2006-01-09
KR20050083926A (ko) 2005-08-26

Similar Documents

Publication Publication Date Title
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR0211284A (pt) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, a respectiva preparação e a respectiva aplicação em terapêutica
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0212069A (pt) Agentes antidiabéticos orais
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BR9916633A (pt) Benzopiranos e benzoxepinas, composições farmacêuticas compreendendo-as e processo de preparação
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR9706387A (pt) Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos
BR9706386A (pt) Antagonistas do receptor de vitronectina, sua preparação e seu us0
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
BR9905089A (pt) Derivados macrolìdeos
BR0210207A (pt) Derivados de pirrolidina como inibidores do fator xa
BR0316307A (pt) Compostos, processo de preparação dos mesmos, composição farmacêutica e utilização dos compostos
BR0214937A (pt) Processo de preparação de derivados de equinocandina
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GALAPAGOS SAS (FR)

Free format text: ALTERADO DE: PROSKELIA SAS

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: GALAPAGOS SAS (FR)

B25A Requested transfer of rights approved

Owner name: GALAPAGOS NV (BE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.